2024-10-05 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods company.

**1. Performance vs. S&P 500 (VOO):**

JNJ's cumulative return is 34.51% compared to VOO's 131.45%, resulting in a significant lag of -96.94%. The relative divergence is 7.36%, indicating that JNJ's performance is currently at the 7.36% percentile of its historical performance range relative to VOO.

**2. Recent Price Action:**

* **Closing Price:** $161.17
* **5-Day Moving Average:** $161.89
* **20-Day Moving Average:** $164.15
* **60-Day Moving Average:** $160.73

**3. Technical Indicators:**

* **RSI:** 36.24 -  The RSI suggests that JNJ is currently in oversold territory.
* **PPO:** -0.39 - The PPO indicates a bearish momentum.
* **Delta_Previous_Relative_Divergence:** -10.01 - The recent relative divergence has been decreasing, suggesting a potential short-term downtrend.
* **Expected Return:** 0.0% - This indicates a potential 5-year expected return of 0% over VOO, considering the current invested amount.

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-07-25 | 1.95    | 22.45 B$     |
| 2024-05-01 | 1.35    | 21.38 B$     |
| 2024-02-16 | 1.68    | 21.39 B$     |
| 2023-10-27 | 10.32   | 21.35 B$     |
| 2024-02-16 | 10.32   | 21.35 B$     |

The most recent earnings (2024-07-25) reported EPS of 1.95 and revenue of 22.45 B$, slightly exceeding analyst estimates. Despite the recent positive earnings, the overall trend shows a decline in both EPS and revenue compared to previous quarters. 

**5. News and Recent Issues:**

Recent market sentiment towards JNJ has been mixed. Some analysts highlight the company's strong brand recognition, diverse product portfolio, and robust cash flow. However, concerns remain around the company's exposure to potential litigation related to its talcum powder products and ongoing competition in the pharmaceutical sector.

**6. Comprehensive Analysis:**

JNJ is currently lagging behind the market (VOO) and experiencing some downward momentum. The company's recent earnings beat expectations, but the overall trend in EPS and revenue is declining. Technical indicators suggest an oversold situation but also potential for a short-term downtrend. While JNJ remains a strong brand with a diversified portfolio, investors should be aware of the risks related to litigation and competition.  

**7. Recommendations:**

Given the current situation, investors should consider the following:

* **Long-Term Investors:** Continue holding JNJ with a long-term outlook, considering the company's strong fundamentals and dividend payments.
* **Short-Term Traders:** Monitor the stock closely for potential short-term opportunities but exercise caution due to the current downtrend.
* **New Investors:** Research the company thoroughly and consider the risks before investing, particularly regarding litigation and competition.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. Please consult with a financial professional before making any investment decisions. 
